
Vision
To become a trusted commercialisation partner in Vietnam for scientifically valuable pharmaceutical and medical-technology solutions, connecting manufacturers' objectives with clinical needs and treatment practice.
Foreword
Dear Partners,
The growth of Vietnam's healthcare market is opening new opportunities for the pharmaceutical sector. Alongside the demand for access to advanced treatments, the health system increasingly seeks science-based solutions that fit clinical practice and improve the effectiveness of medicine use.
Since 2007, Ngoc Thien has developed its pharmaceutical operations, building partnerships with more than 15 international partners from 7 countries and territories, and supplying medicines to nearly 900 healthcare facilities nationwide. Nearly twenty years in the Vietnamese market have given us a deep understanding of the pharmaceutical business environment, the needs of healthcare facilities, and how to connect the direction of international partners with real conditions for local execution.
On that foundation, Ngoc Thien defines its role as a commercialisation partner in Vietnam for pharmaceutical manufacturers and medical-technology companies. We connect registration, distribution and market development with the clinical needs of hospitals, thereby helping build a fitting and sustainable presence for our partners' products.
Respectfully,
Our story
Established in 2007, Ngoc Thien has steadily built its pharmaceutical business capability, its relationships with international partners and its hospital customer base. A journey of nearly two decades has taught the company how a product moves from a clinical need to the trust of physicians and access for patients.
Today, Ngoc Thien serves as a commercialisation partner in Vietnam for pharmaceutical and medical-technology manufacturers — connecting registration, distribution and market development with the clinical needs of hospitals.
Development milestones
Ngoc Thien Trading and Pharmaceutical Joint Stock Company is founded in Phu Tho.
Representative office opens in Hanoi.
QDU Pharma is established as part of the Ngoc Thien ecosystem.
Representative office opens in Ho Chi Minh City.
Construction begins on the 9,000 m² Ngoc Thien plant built to EU-GMP standards, alongside a 2.7-hectare organic mulberry cultivation area.
The company moves to direct importation, taking ownership of the full chain from marketing authorisation to delivery.
Vision & Mission

To become a trusted commercialisation partner in Vietnam for scientifically valuable pharmaceutical and medical-technology solutions, connecting manufacturers' objectives with clinical needs and treatment practice.

Connecting quality products with clinical needs through responsible execution, transparent information and long-term partnership.
Core values
Fully honouring our commitments to partners, healthcare facilities and patients.
Sharing information clearly, without avoiding what is not yet perfect.
Evidence and clinical need are the basis for every development decision.
Persistently investing in people, science and solutions of real practical value.
Licences & certifications
· No. 2500268633
· First issued 07/02/2007
· 12th amendment on 26/06/2026
· No. 4563/ĐKKDD-PT
· Wholesale of medicines
· Ambient and cold storage
· Eligible to trade class B, C and D
· Declaration No. 170000005/PCBMB-VP
| 12-26/GDP | Good Distribution Practice (GDP) — Phu Tho warehouse | |
|---|---|---|
| 1886/1/GDP | Good Distribution Practice (GDP) — Hanoi warehouse | |
| 2163/GDP | Good Distribution Practice (GDP) — Ho Chi Minh City warehouse | |
| 01-1886/ĐKKDD-HNO/ĐC | Eligible for pharmaceutical trading — Hanoi warehouse | |
| 12881/ĐKKDD-HCM | Eligible for pharmaceutical trading — Ho Chi Minh City warehouse |
Full copies of the business registration certificate, pharmaceutical business licence, GDP records and the medical-device trading declaration are available during due diligence.
Development direction
From 2026, Ngoc Thien has moved to direct importation, taking ownership of the entire chain from marketing authorisation to delivery to healthcare facilities. In parallel, the company is developing a pharmaceutical manufacturing plant oriented toward EU-GMP standards, expected to become operational from 2028.